Kestra Medical Technologies (NASDAQ:KMTS) Hits New 12-Month High - Time to Buy?

Key Points

• Kestra Medical Technologies reached a new 52-week high of $26.83, closing at $26.72 after trading 66,223 shares.
• The company has a consensus price target of $27.33 with a current rating of "Moderate Buy" from five analysts, despite Wells Fargo lowering their target from $28 to $27.
• Several hedge funds have recently increased their stakes in Kestra, indicating positive institutional interest in the stock.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as $26.83 and last traded at $26.72, with a volume of 66223 shares changing hands. The stock had previously closed at $25.20.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wall Street Zen raised Kestra Medical Technologies from a "sell" rating to a "hold" rating in a report on Saturday. Wells Fargo & Company dropped their target price on Kestra Medical Technologies from $28.00 to $27.00 and set an "overweight" rating for the company in a report on Thursday, July 17th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, Kestra Medical Technologies currently has a consensus rating of "Moderate Buy" and a consensus target price of $27.33.

Kestra Medical Technologies Price Performance

The stock has a 50 day moving average of $17.53 and a 200 day moving average of $20.02. The company has a debt-to-equity ratio of 0.23, a current ratio of 6.84 and a quick ratio of 6.84.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Yu Fan acquired a new position in Kestra Medical Technologies in the first quarter valued at about $56,880,000. T. Rowe Price Investment Management Inc. bought a new position in Kestra Medical Technologies in the first quarter valued at about $56,613,000. Omega Fund Management LLC bought a new position in Kestra Medical Technologies in the first quarter valued at about $44,754,000. Alliancebernstein L.P. grew its position in Kestra Medical Technologies by 10.8% in the second quarter. Alliancebernstein L.P. now owns 1,312,085 shares of the company's stock valued at $21,754,000 after acquiring an additional 128,312 shares during the last quarter. Finally, Eventide Asset Management LLC grew its position in Kestra Medical Technologies by 285.7% in the second quarter. Eventide Asset Management LLC now owns 1,060,557 shares of the company's stock valued at $17,584,000 after acquiring an additional 785,557 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.